Kornimate/medical-research-clean huggingface dataset:
effect of body weight change to surgical icu outcomes

Conditions: Body Weight; Weight Change

Summary: aims of study 1. effect of daily weight change upto 7 days from icu admission to outcome of treatment in 28 days 2. determination cut point of maximum weight change to outcome treatment

study type : prospective observational study location : general surgical intensive care unit inclusion criteria : all admission patient with expected survive more than 24 hours exclusion criteria : patient died within 24 hours or who could not be weighed.

Eligibility criteria:
inclusion criteria: * all admitted icu patients expected survive more than 24 hours exclusion criteria: * all expected icu patients survive less than 24 hours * all patient cannot be weighed.

Keywords: body weight body mass index weight change icu outcomes
the efficacy of the acupuncture in the treatment of systemic arterial hypertension

Conditions: Arterial Hypertension

Summary: there are few studies in the treatment of hypertension employing acupuncture as a blood pressure regulating technique. the ministry of health synthesized the inclusion of integrative and complementary practices within the unique health system, such as acupuncture. our objective is to verify the effect of the acupuncture session on hypertensive patients, measured through ambulatory blood pressure monitoring (abpm). in this way two groups of patients will be selected in a randomized clinical trial. in the first group, chinese traditional acupuncture will be applied and in the second group the acupuncture sham will be applied.

acupuncture as therapy is the subject of conflicting opinions on its effectiveness in scientific means, because in spite of its long existence as a therapeutic tool, raises doubts on the standards of western science model. in addition, there are few studies in the treatment of hypertension employing acupuncture as a blood pressure regulating technique. the ministry of health synthesized the inclusion of integrative and complementary practices within the unique health system, such as acupuncture. the world health organization (who) recognizes its effectiveness, having its own concept in the energy imbalance that alter the organic, mental and emotional part addressing a current issue proposing to groundbreaking research. the objective is to verify the effect of the acupuncture session on hypertensive patients, measured through ambulatory blood pressure monitoring (abpm). in this way two groups of patients will be selected in a randomized clinical trial. in the first group, chinese traditional acupuncture will be applied and in the second group the acupuncture sham will be applied.

Eligibility criteria:
inclusion criteria: * patients enrolled in stage i to iii of systemic arterial hypertension * signing the free and informed consent term exclusion criteria: * patients who do not agree to participate in the study * patients with systolic pressure values greater than 180 mmhg or diastolic pressure above 110 mmhg * patients with important comorbidities

Keywords: arterial hypertension acupuncture
intracranial aneurysms and cognitive function

Conditions: Intracranial Aneurysms

Summary: the prevalence rate of intracranial aneurysms in the adult population is close to 5%. rupture risk of such aneurysms causing subarachnoid hemorrhage (sah) can be substantial.most patients suffering from an aneurysmal sah are in their mid life, i.e., 30 to 60 years old. aneurysmal sah may cause disability and mortality. the present study includes a follow-up study and a cross-sectional fmri study. the purpose of the follow-up study is to monitor patients receiving prophylactic surgical treatment of their un-ruptured aneurysms to examine whether such treatment is associated with cognitive, psychosocial and/or neurologic sequela. the purpose of the cross-sectional fmri study is to examine the relationship between memory function and brain activity among sah patients. memory impairment is often found among aneurysmal sah patients. using fmri can possibly shed some light on whether such memory impairment may be caused by diffuse cerebral damage or a focal damage at the aneurysm site.


Eligibility criteria:
inclusion criteria: * patients with un-ruptured aneurysms in the anterior communicating artery and the middle cerebral artery. * a subgroup of patients suffering aneurismal subarachnoid hemorrhage. exclusion criteria: * history of earlier cerebrovascular, psychiatric or neurological disease. * age older than 75 years * lack of fluency in norwegian * alcohol or substance abuse * aphasia * substantial vision or hearing deficits
effect of shockwave therapy on low back pain in primary dysmenorrhea

Conditions: Dysmenorrhea; Back Pain Lower Back

Summary: primary dysmenorrhea (pd), defined as menstrual pain without any structural lesions, usually begins shortly before or immediately after the onset of the menstrual cycle and commonly lasts for 48 to 72 hour

dysmenorrhea is one of the most common gynecological conditions in women. primary dysmenorrhea (pd), defined as menstrual pain without any structural lesions, usually begins shortly before or immediately after the onset of the menstrual cycle and commonly lasts for 48 to 72 hour. it is accompanied by general symptoms, such as nausea and vomiting, malaise, weakness, lower backache, and diarrhea. in ovulatory cycles, women secrete high levels of or have increased sensitivity to prostaglandins. these prostaglandins may stimulate myometrial contractions and sensitize pain fibers, and thus induce pelvic pain. females of reproductive age often suffer from dysmenorrhea, a painful condition. despite dysmenorrhea being generally considered a benign condition, a significant disability can result from it. researchers suggest that dysmenorrhea has been linked to migraines, headaches, and fibromyalgia, among other painful disorders. the authors reported further evidence that dysmenorrhea can alter noxious sensory processing. primary dysmenorrhea usually begins six to 12 months after menarche and is characterized by spasmodic cramping pain in the lower abdomen that can radiate to the lower back and anterior or inner thighs. the pain usually has a clear temporal pattern: it begins a few hours before or at the start of menstruation, is most intense at onset, gradually waning over two to three days. the purpose of this study was to investigate the effectiveness shockwave therapy on low back pain in primary dysmenorrhea.

Eligibility criteria:
inclusion criteria: * their ages ranged from 18 to 30 years. * their bmi were not exceeding 29 kg/m2. * all patients were clinically diagnosed as low back pain during primary dysmenorrhea according to the primary dysmenorrhea consensus guideline exclusion criteria: * any known chronic disease (such as cardiovascular or renal diseases) or secondary dysmenorrhea. * being pregnant or planning to get pregnant any time during the trial. * having received other treatments for pd in the past half year. * irregular menstrual cycles. * mental or neurological disorder

Keywords: dysmenorrhea lower back pain shock wave
robotic vs. laparoscopic vs. open living donor hepatectomy

Conditions: End Stage Liver Disease; Acute Liver Failure; Acute-On-Chronic Liver Failure; Hepatocellular Carcinoma

Summary: this will be a study to examine the outcomes of open, laparoscopic, and robotic living donor liver transplantation (ldlt) procedures. the analysis will encompass 3,448 cases (1,724 donor-recipient pairs) from january 2011 to march 2023, documenting the transition between these surgical techniques, with a noted crossover in 2018.

background: liver transplantation is a primary treatment for end-stage liver disease, enhancing survival rates and life quality. living donor liver transplantation (ldlt) has gained prominence due to the scarcity of deceased donor organs. historically, the open technique dominated living donor hepatectomies. however, advances in minimally invasive surgery (mis) led to laparoscopic and later robotic procedures. with the introduction of robotic surgery, mis for complex surgeries improved, offering better precision and ergonomics. objective: to compare the short and long-term outcomes of open, laparoscopic, and robotic ldlt, focusing on both donors and recipients. methods: study design: retrospective analysis of data from a prospective liver transplant registry, examining three ldlt techniques. setting: king faisal specialist hospital and research centre, riyadh, saudi arabia. participants: all consecutive living donor and recipient pairs undergoing ldlt between january 2011 and march 2023. exclusions include dual or domino ldlt. surgical techniques: open, laparoscopic, and robotic techniques used for donor hepatectomies. variables: primary focus on morbidity, conversion rates, and in-hospital mortality for both donors and recipients. secondary variables will include major complications, graft, and recipient survival rates. data sources and measurement: data sourced from a secured, encrypted transplant database, detailing patient data, operation characteristics, and post-op outcomes. complication severity will be captured using the clavien-dindo classification and comprehensive complication index™. study size: determined by the total number of procedures during the study duration, deemed sufficient for comparison. quantitative variables: demographics, comorbidities, operational details, post-op and long-term outcomes. statistical methods: various statistical tests will be employed for comparison, including the student t, mann-whitney u, one-way anova, fischer and chi square. survival will be evaluated using the kaplan-meier method. multivariable binary logistic regression will be employed. all statistical analyses will be conducted using r. ethics approval: obtained (id: rac 2121012) and in accordance with the 1964 helsinki declaration.

Eligibility criteria:
inclusion criteria: * all donor and recipient pairs that underwent ldlt at the study institution * between 01 january 2011 to 31 march 2023 * both adult-to-adult and adult-to-pediatric ldlt are included. exclusion criteria: * dual and domino ldlt are excluded.
ceftazidime-avibactam compared with doripenem followed by oral therapy for hospitalized adults with complicated utis (urinary tract infections)

Conditions: Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis

Summary: the purpose of this study is to evaluate the effects of ceftazidime avibactam compared to doripenem for treating hospitalized patients with complicated urinary tract infections, including acute pyelonephritis

a phase iii, randomized, multicenter, double-blind, double dummy, parallel group, comparative study to determine the efficacy, safety, and tolerability of ceftazidime avibactam (caz-avi, formerly caz104) versus doripenem followed by appropriate oral therapy in the treatment of complicated urinary tract infections, including acute pyelonephritis, with a gram negative pathogen in hospitalized adults

Eligibility criteria:
inclusion criteria: * 18 to 90 years of age inclusive * female patients can participate if they are surgically sterile or completed menopause or females capable of having children and agree not to attempt pregnancy while receiving iv study therapy and for a period of 7 days after * has pyuria with \>/= 10 wbcs (white blood cell) and has a positive urine culture within 48 hours of enrollment containing \>/=10 to the fifth cfu (colony forming unit ) /ml of a recognized uropathogen known to be susceptible to iv study therapy (caz-avi and doripenem) * demonstrates either acute pyelonephritis or complicated lower uti without pyelonephritis exclusion criteria: * urine pathogen is a gram-positive pathogen or a uropathogen resistant to caz-avi or doripenem * patient's urine culture at study entry isolates more than 2 microorganisms regardless of colony count or patient has a confirmed fungal uti * patient is receiving hemodialysis or peritoneal dialysis or had a renal transplant * patient is immunocompromised * patient is considered unlikely to survive the 6- to 8-week study period or has a rapidly progressive or terminal illness including septic shock which is associated with a high risk of mortality

Keywords: ceftazidime, avibactam, doripenem, ciprofloxacin, sulfamethoxazole/trimethoprim, anti-infective agents, complicated urinary tract infection,acute pyelonephritis
intravenous lidocaine for laparoscopic cholecystectomy

Conditions: Postoperative Pain; Opioid Consumption

Summary: intravenous lidocaine has been shown to have analgesic, antinflammatory, antihyperalgesic, antithrombotics and neuroprotective properties. in a previous study conducted in patients undergoing laparoscopic cholecystectomy under general anesthesia with desflurane and fentanyl, intraoperative i.v. infusion of lidocaine spared opioids consumption in the recovery room by 30%. the purpose of this study was to determine if an i.v. infusion of lidocaine without intraoperative opioids would reduce the amount of fentanyl to the same extent and opioids-related side effects.


Eligibility criteria:
inclusion criteria: * patients undergoing laparoscopic cholecystectomy exclusion criteria: * age \ 85 yr, * asa physical status 3 and greater, history of hepatic failure (child \& pug a-c), * renal failure (creatinine outside the normal range) or cardiac failure (nyha i-iv), * adams-stoke syndrome, * severe degrees of sinoatrial, atrioventricular or intraventricular block, * organ transplant, * diabetes mellitus type 1 and 2, * morbid obesity (bmi \> 40), * chronic use of opioids and beta-blockers, * known seizures, * severe mental impairment, * allergy to local anesthetics and to all the medications used in the study, or * inability to understand pain assessment.

Keywords: intravenous lidocaine postoperative pain laparoscopic surgery opioids opioids side-effects
high intensity focused ultrasound (hifu) treatment of basal cell carcinoma

Conditions: Basal Cell Carcinoma

Summary: the overall objective of the study is to evaluate the safety and efficacy of treatment of basal cell carcinoma (bcc) using a new modality based on high-intensity focused ultrasound (hifu). bcc is the most common type of skin cancer in europe, australia and the us. it accounts for more than 75% of all skin cancer cases in those regions. there are currently more the 14000 bcc cases registrations in poland every year, and occurrences on a global scale are counted in several millions per year. given the trend of aging population those numbers will only increase with time. finding new and more effective treatment methods are therefore highly relevant from both a clinical and socioeconomic perspective. the investigational device used in the study is a system capable of making controlled and targeted thermo-mechanical treatment of small intradermal volumes containing e.g. bcc cells, but without inflicting damage to the surrounding tissue. the investigation involves an evaluation of the safety and efficacy profile 3 months after a single few-minute treatment. subsequent follow-up of secondary endpoints is done every third month until the end of the study one year after the treatment.


Eligibility criteria:
inclusion criteria: * subjects of each gender aged 18 years or older at the time of informed consent. there is no upper limit of age. * subjects who have received oral and written study information, accepted participation and signed the informed consent document. * subjects who are willing and mentally and physically capable to understand and follow the treatment and follow-up schedule including post-treatment care instructions. * subjects who are willing to have photographs and images taken of the treated lesions to be used anonymously or coded in evaluations and publications. * subjects, who have histologically and clinically verified basal cell carcinoma cancer of thickness not more 2.0 mm measured by ultrasound imaging or histopathological examination. exclusion criteria: * subjects who are less than 18 years at the time of informed consent. * subject is pregnant or lactating at time of first treatment * subjects with extensive, invasive or advanced skin cancer when another method in use such as radiotherapy or mohs' surgery has priority and offers the patient better opportunity of cure. * cancers on anatomical sites where the ultrasound probe cannot be adapted for anatomical reasons * any systemic disease that according to investigator's assessment may interfere with the spontaneous course of a skin cancer. * any condition predisposing to treatment-related adverse effects or complications from the ultrasound treatment. * subjects with abnormal scar formation * subjects with impaired wound healing * subjects with any other acute or chronic condition which, in the opinion of the investigator, could interfere with the conduct of the study * subjects undergoing immunosuppressive treatment

Keywords: skin cancer hifu bcc dermatology high intensity focused ultrasound dermoscopy
the value of lymph node dissection of indocyanine green-guided near-infrared fluorescent imaging in esophagectomy

Conditions: Esophageal Cancer; Indocyanine Green

Summary: indocyanine green (icg) has been recently introduced in clinical practice as a fuorescent tracer. lymphadenectomy is particularly challenging in esophageal cancer surgery, owing to the complex anatomical drainage.therefore, the purpose of this study was to explore whether the nir-icg imaging system could accurately assess the lymph node markers during radical resection of esophageal cancer.

this study will be accepted in esophageal cancer patients with radical esophag-ectomy as the research object.we will divide them into two groups: experimental group for injection of indocyanine green group and control group for injectable in-docyanine green group.we will compare with the accuracy,false positive rate and false negative rate,sensitivity, specificity and related indicators of intraoperative lymph node cleaning,in order to explore the common position of esophageal cancer sentinel lymph node,guidance of esophageal cancer lymph node cleaning thoroughly.

Eligibility criteria:
inclusion criteria: 1. age and gender: 18-75 years old, male and female unlimited; 2. preoperative biopsy was pathologically diagnosed as esophageal squamous cell carcinoma; 3. preoperative combination with neoadjuvant chemoradiotherapy; 4. surgical resection of esophageal carcinoma under endoscopic selection and intraoperative anastomosis; 5. heart, lung, liver and kidney functions can tolerate operation; 6. patients and their family members can understand and are willing to participate in this clinical study and sign the informed consent. exclusion criteria: 1. allergic to icg or iodine; 2. patients with a history of chest surgery or thoracic lymph node dissection; 3. patients needing emergency surgery; 4. patients whose tumors involve neighboring organs and need to be removed by combining organs; 5. patients with tumor recurrence or distant metastasis; 6. patients who had participated in or were participating in other clinical trials within the previous 4 weeks were included; 7. a history of serious mental illness; 8. pregnant or lactating women; 9. patients with other conditions considered by the researcher should not participate in the study.

Keywords: esophageal cancer indocyanine green the lymph node markers
preoperative transhepatic arterial chemotherapy (tac) in the treatment of liver metastasis of resectable colorectal cancer

Conditions: Colorectal Cancer

Summary: the purpose of this study is to investigate whether preoperative tac is able to improve progression free survival and overall survival in patients receiving liver metastasis resection of colorectal cancer.

we administered tac(oxaliplatin,fudr and mmc) 7 days before liver metastasis resection of colorectal cancer. the study endpoints were progression free survival and overall survival as evaluated by intent-to-treat analysis.

Eligibility criteria:
inclusion criteria: * age \<= 75 years * resectable liver metastasis * remnant liver volume \>= 70% * without other organ metastasis or peritoneum metastasis * without contradiction of cardiac and pulmonary diseases exclusion criteria: * age \> 75 years * unresectable liver metastasis * remnant liver volume \< 50% * with other organ metastasis or peritoneum metastasis * with contradiction of cardiac and pulmonary diseases

Keywords: colorectal cancer liver metastasis neoadjuvant chemotherapy
evaluation of lovastatin in severe persistent asthma

Conditions: Severe Persistent Asthma

Summary: this study has two purposes: 1. to determine whether lovastatin, a commonly used medication to lower cholesterol in the blood, can produce beneficial changes in airway inflammation and in the airway smooth muscle 2. to examine whether lovastatin will have favorable changes in asthma symptoms of patients with moderate or severe asthma.


Eligibility criteria:
inclusion criteria: * age \> 18 years to \<65 years * severe persistent asthma (per 2002 national asthma education and prevention program guidelines) * treatment with daily fluticasone (500 ug bid) and salmeterol (50 ug bid) during the past 4 or more weeks * pre-bronchodilator fev1 \<80% predicted * post-bronchodilator improvement in fev1 of at least 12% and 200 ml or a pc20 to methacholine of \<8 mg/ml * evidence of inadequate asthma control in the past 2 weeks: use of rescue inhaler \> 4 days and \>8 occasions in the past 2 weeks, daytime asthma symptoms \> 4 days in the past 2 weeks, or 1 or more nocturnal awakening in the past 2 weeks * no evidence of alternate diagnosis (e.g., sarcoidosis, eosinophilic pneumonia) on bronchoscopy performed as part of routine care in the refractory obstructive lung disorders clinic. * completed research bronchoscopy while on current dose of daily fluticasone and salmeterol within 4 weeks of meeting other inclusion criteria. note: many patients in the rold clinic require a bronchoscopy to confirm the diagnosis of asthma and exclude other diagnosis (e.g., sarcoidosis). these patients are asked to participate in a research protocol (separate from this proposal) that allows investigators to collect additional samples (endobronchial biopsies, bronchoalveolar lavage fluid, endobronchial brushings) at the end of the clinical portion of the bronchoscopy {irb protocol # 15361a entitled, "airway inflammation in refractory obstructive lung disease (rold): understanding markers of inflammation and remodeling"}. this protocol was recently submitted to the irb in march 2007. exclusion criteria: * pregnancy or lactation * severe metabolic disease * other respiratory or inflammatory disorders (sarcoidosis, emphysema) * hypokalemia, dehydration * uncontrolled seizure disorder ( 2 or more seizures in last year) * major surgery, trauma * pre-existing liver disease (ast or alt \>10% above the upper limit of normal) * elevated ck (\>50% above the upper limit of normal) * history of alcohol abuse * current smokers or ex-smokers with \> 10 pack-years of smoking * partial ileal bypass surgery * concurrent treatment with drugs known to be have potential interactions or associated with rhabdomyolysis (cimetadine, danazole, delavaridine, diltiazem, fenofiibrate, nefazodone, niacin, protease inhibitors, quinipristoline/dalfopristin, ranolazine, rifampin, telbivudine, telithromycin) * hiv patients taking protease inhibitors * history of allergy or intolerance to statin * use of 1 or more doses of any cholesterol lowering medication in the previous 12 weeks * clinical indication for treatment with statins

Keywords: asthma